Connect your AI

Greif GEF Other Noncash Income (Expense)

Other Noncash Income (Expense) at other companies

West Pharmaceutical ServicesWST

——

ConstelliumCSTM

——

Other financials

Income statement

Revenue$1.1B-0.5%

Gross profit$247.0M-0.6%

Operating income$35.4M-41.7%

Net income$12.6M-68.4%

EPS (diluted)$1.16-24.6%

Balance sheet

Cash & equivalents$286.1M+42.3%

Total debt$1.2B-60.8%

Total equity$2.9B+44.2%

Total assets$5.6B-15.0%

Cash flow

Operating cash flow$116.6M+479%

CapEx$56.8M+59.1%

Free cash flow$59.8M+190%

Valuation

Market cap$3.92B+19.8%

Enterprise value$4.83B-21.7%

P/E13.1×-3.8×

P/S0.9×+0.1×

Profitability

Gross margin22.4%+1.6pp

Operating margin10.5%+3.4pp

Net margin6.5%+2.3pp

FCF margin5.8%—

Returns & leverage

Return on equity12%+2.4pp

Debt / equity0.4×-1.1×

Current ratio1.3×0.0×

Where this comes from

Reported directly by Greif in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Greif’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Greif's other noncash income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Greif's other noncash income (expense)?: Greif (GEF) reported other noncash income (expense) of -$400K in Q1 2026.
How has Greif's other noncash income (expense) changed year-over-year?: Greif's other noncash income (expense) decreased by 0.0% year-over-year, from -$400K to -$400K.